Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PBYI

Puma Biotechnology, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PBYI. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.52

Puma Biotechnology, Inc. (NASDAQ: PBYI) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 02:24 UTC.

What Puma Biotechnology, Inc. does

Puma Biotechnology is a biopharmaceutical company that develops and commercializes products for cancer treatment. The company currently commercializes NERLYNX, an oral tyrosine kinase inhibitor used to treat certain HER2-positive breast cancers, which is approved in the United States and has received approval in more than 40 countries outside the United States.

Summarized from Puma Biotechnology, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.52
Return on equity23.87%
Debt/equity0.17

Revenue, margins & earnings

FY2021: net loss $29M on revenue $253M$253MFY2021FY2022 Taxes & interest: $24MFY2022 Operating costs: $204M$228MFY2022FY2023 Net income: $22MFY2023 Taxes & interest: $11MFY2023 Operating costs: $203M$236MFY2023FY2024 Net income: $30MFY2024 Operating costs: $200M$230MFY2024FY2025 Net income: $31MFY2025 Taxes & interest: $6MFY2025 Operating costs: $191M$228MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-16
  • 2026-09-16DirectorOption exercise50,000$146.5K
  • 2026-09-16DirectorStock OptionOption exercise-50,000—
  • 2026-09-16DirectorSale-5,000$45.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Puma Biotechnology, Inc. do?

Puma Biotechnology is a biopharmaceutical company that develops and commercializes products for cancer treatment.

When did PBYI last file with the SEC?

Puma Biotechnology, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-16. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 02:24 UTC. This page is also available as JSON at /api/data?ticker=PBYI and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PBYI and 5,000+ tickers.

Create a free account — keep PBYI
For your agent
GET /api/data?ticker=PBYI

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt